• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Clinical and experimental allergy : >Evidence of in vivo basophil activation in chronic idiopathic urticaria.
【24h】

Evidence of in vivo basophil activation in chronic idiopathic urticaria.

机译：慢性特发性荨麻疹体内嗜碱性粒细胞活化的证据。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Background Approximately 40% of chronic idiopathic urticaria (CIU) subjects have autoantibodies to either FcepsilonRIalpha or IgE. The effect of such autoantibodies on circulating basophil activation status is unknown. Objective The expression of cell surface activation markers on basophils from CIU, non-allergic, and allergic subjects were compared. Further, the relationship between marker expression and serum factors reported in CIU, such as histamine-releasing activity (HRA) and immunoreactivity to FcepsilonRIalpha were examined. Methods Peripheral blood was obtained from CIU, allergic, and non-allergic donors and fractionated by density gradients. Enriched basophils (1-12%) were analysed by flow cytometry for expression of activation markers including CD63, CD69, and CD203c. Dilutions of serum (5-50%) were analysed for HRA on basophils from a normal donor. Serum was tested for immunoreactivity by western blotting to a standard cell lysate prepared from an RBL-SX38 cell line transfected with human FcepsilonRIalpha. Results CIU subjects (n=9) and allergic subjects (n=8) exhibited enhanced expression of CD63 and CD69, as compared with non-allergic subjects (n=7); however, no difference was seen among groups for CD203c expression. Five CIU and two non-allergic subjects had evidence of significant serum HRA (>20%), whereas two CIU, two allergic, and three non-allergic subjects had evidence of serum immunoreactivity to FcepsilonRIalpha. Serum HRA and serum immunoreactivity to FcepsilonRIalpha were not associated with enhanced surface marker expression. Conclusion Basophil activation marker expression is increased in CIU subjects and is not associated with serum factors. In addition, serum HRA and FcepsilonRIalpha immunoreactivity are not unique to CIU, or related to enhanced circulating basophil marker expression.
机译：背景大约40％的慢性特发性荨麻疹（CIU）受试者对FcepsilonRIalpha或IgE具有自身抗体。此类自身抗体对循环嗜碱性粒细胞活化状态的影响尚不清楚。目的比较CIU，非过敏和过敏受试者嗜碱性粒细胞的细胞表面活化标记物的表达。此外，还检查了标志物表达与CIU中报道的血清因子之间的关系，例如组胺释放活性（HRA）和对FcepsilonRIalpha的免疫反应性。方法从CIU，过敏性和非过敏性供体获得外周血，并按密度梯度分级。通过流式细胞术分析富集的嗜碱性粒细胞（1-12％）的活化标记包括CD63，CD69和CD203c的表达。分析了血清稀释液（5-50％）对正常供体嗜碱性粒细胞的HRA。通过蛋白质印迹法检测血清的免疫反应性，该蛋白质印迹法是从用人FcepsilonRIalpha转染的RBL-SX38细胞系制备的标准细胞裂解液中进行的。结果与非过敏性受试者（n = 7）相比，CIU受试者（n = 9）和过敏性受试者（n = 8）的CD63和CD69表达增强。但是，各组之间在CD203c表达上没有差异。 5名CIU和2名非过敏性受试者有明显的血清HRA证据（> 20％），而2名CIU，2名过敏性和3名非过敏性受试者具有对FcepsilonRIalpha的血清免疫反应性的证据。血清HRA和血清对FcepsilonRIalpha的免疫反应性与增强的表面标志物表达无关。结论CIU受试者嗜碱性粒细胞活化标志物表达增加，与血清因子无关。此外，血清HRA和FcepsilonRIalpha免疫反应性不是CIU独有的，或与循环嗜碱粒细胞标志物表达增强无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号